Skip to content

Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD

Multiple Myeloma

The purpose :

Detect and profile Multiple myeloma Measurable Residual Disease(MRD) prognostics for monitoring post-transplant Multiple Myeloma (MM) Patients receiving maintenance therapy.

null

Conditions de participation

  • Sexe:

    ALL

  • Âges admissibles:

    18 and up

Critères de participation

Inclusion Criteria:

* Confirmed MM diagnosis
* Transplant eligible patients in a first remission
* Known MRD level detected by ClonoSeq (other IMWG recognized methodologies can be also employed)
* Availability of deidentified patient's demographic and clinical follow up data
* Receiving standard of care treatment
* Able to provide informed consent

Exclusion Criteria:

* Failure to meet inclusion criteria

Lieu de l'étude

Jewish General Hospital
Jewish General Hospital
Montreal, Quebec
Canada

Contactez l'équipe d'étude

Primary Contact

Rayan Kaedbey, MD

[email protected]
514 340 8222
Étude parrainée par
Sir Mortimer B. Davis - Jewish General Hospital
Participants recherchés
Plus d'informations
ID de l'étude: NCT05530096